All Hong Kong stocks quotes are at least 15 minutes delayed.
02268
WUXI XDC
HKD
61.150-0.550
(-0.89%)
1D
AI Analysis for 02268
AI Analysis
High
60.050
Open
56.600
VWAP
58.24
Vol
6.72M
Mkt Cap
82.15B
Low
56.600
Amount
391.54M
EV/EBITDA(TTM)
32.08
Total Shares
1.26B
EV
8.40B
EV/OCF(TTM)
--
P/S(TTM)
11.59
WuXi XDC Cayman Inc is an investment holding company principally engaged in the provision of comprehensive contract research, development and manufacturing organization (CRDMO) services for antibody drug conjugate (ADC) and other bioconjugates. The Company's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The Company provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The Company principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.
Show More
News
6.5
03-02aastocks<M Stanley Research>: WUXI XDC (02268.HK) Expected to See Significant Share Price Increase in the Next 30 Days
Morgan Stanley's Outlook: Morgan Stanley predicts that WUXI XDC's share price will rise in the next 30 days due to its recent decline, making it more attractive for short-term valuation.
Out-Licensing Agreement: WUXI XDC has announced a significant out-licensing agreement for its payload-linker technology, which includes upfront payments, milestone payments, and potential sales royalties to enhance sales and profitability.
Broker Rating: The broker has rated WUXI XDC as Overweight, setting a target price of $86 for the stock.
Short Selling Data: As of the latest data, WUXI XDC has a short selling amount of $62.57 million, with a short selling ratio of 13.437%.
2.0
02-27aastocks<Research>CLSA: Thursday's Drop in WUXI BIO/WUXI XDC Not Based on Fundamental Factors
Market Performance: WUXI BIO and WUXI XDC experienced declines of approximately 7% and 8% respectively, while Hong Kong-listed CRO/CDMO companies overall lost between 2% to 9%.
Analysis of Decline: CLSA's report attributes the decline to technical factors and capital flow rather than fundamental issues, suggesting that the pullback is a short-term volatility rather than a sign of weakening demand.
4.5
02-24aastocksHSI Drops Over 500 Points; Meituan, Chinese Insurers and Pharmacies Underperform; Standard Chartered Remains Strong; Knowledge Atlas and MiniMax Recover
Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.
Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.
Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.
AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.
6.0
02-20aastocksM Stanley Lowers Price Target for WUXI XDC (02268.HK) to HKD86, Maintains Overweight Rating
Earnings Forecast Adjustment: WUXI XDC disclosed a decline in operating margins for 2025, leading Morgan Stanley to reduce its earnings forecast for 2026-30 by 1-2% and adjust the target price from HKD88 to HKD86.
Positive Long-term Outlook: Despite the short-term challenges, Morgan Stanley predicts a 36% CAGR for WUXI XDC's adjusted net profit from 2024 to 2027, assigning an Overweight rating due to expectations of profit growth, margin expansion, and industry leadership.
2.0
02-13aastocksS Korean Investors' Top HK Stock Purchase This Year: MINIMAX, Totaling USD 20.7M
Top Stock Purchases: As of February 10, 2026, South Korean investors' most purchased stock on the Hong Kong Stock Exchange is MINIMAX-WP (00100.HK) with a net purchase of approximately USD20.7 million, followed by CAM CSI300 (03188.HK) and MONTAGE TECH (06809.HK).
Shift in Investment Focus: Compared to 2025, South Korean investors are increasingly targeting China's emerging industries and tech companies, indicating a strategic shift in their investment approach.
Money Flow
Over the past 66 trading days, overall net money flow is 135.48M, with retail investors contributing 29.37M and major investors adding 69.54M.
Net Buy $ Volume
Net Sell $ Volume
Goldman Sachs
Goldman Sachs
Buy
maintain
2026-03-25
Reason
Goldman Sachs maintained a 'Buy' rating for WUXI XDC due to strong revenue growth of 35.9% year-over-year and a net profit increase of 26.4% in the second half of 2025. The company's 2026 guidance aligns with expectations, projecting a revenue growth of approximately 35% on a constant exchange rate basis. Although the target price was slightly reduced from $87.1 to $85.9, the positive outlook is supported by the commencement of production at the Singapore plant.
Goldman Sachs
Buy
Price Target
2026-03-25
maintain
Goldman Sachs maintained a 'Buy' rating for WUXI XDC due to strong revenue growth of 35.9% year-over-year and a net profit increase of 26.4% in the second half of 2025. The company's 2026 guidance aligns with expectations, projecting a revenue growth of approximately 35% on a constant exchange rate basis. Although the target price was slightly reduced from $87.1 to $85.9, the positive outlook is supported by the commencement of production at the Singapore plant.
UBS
Buy
downgrade
2026-03-24
Reason
UBS maintains a Buy rating for WUXI XDC due to strong financial results, with significant year-on-year growth in revenue and net profit, and an attractive valuation despite a slight reduction in the target price.
UBS
Buy
Price Target
2026-03-24
downgrade
UBS maintains a Buy rating for WUXI XDC due to strong financial results, with significant year-on-year growth in revenue and net profit, and an attractive valuation despite a slight reduction in the target price.
Morgan Stanley
Morgan Stanley
initiated
$86
2026-03-02
Reason
The analyst rating from Morgan Stanley for WUXI XDC (02268.HK) is based on the belief that the stock's recent price decline has made its short-term valuation more attractive. Additionally, the company announced a significant out-licensing agreement for its payload-linker technology platforms, which includes upfront payments, milestone payments, and potential sales royalties. These factors are expected to boost sales and profitability, leading the broker to rate the stock as Overweight with a target price of $86.
Morgan Stanley
Price Target
$86
2026-03-02
initiated
The analyst rating from Morgan Stanley for WUXI XDC (02268.HK) is based on the belief that the stock's recent price decline has made its short-term valuation more attractive. Additionally, the company announced a significant out-licensing agreement for its payload-linker technology platforms, which includes upfront payments, milestone payments, and potential sales royalties. These factors are expected to boost sales and profitability, leading the broker to rate the stock as Overweight with a target price of $86.
Morgan Stanley
Morgan Stanley
Overweight
downgrade
$88 -> $86
2026-02-20
Reason
The analyst rating for WUXI XDC was assigned an "Overweight" due to several positive factors. Despite a decline in operating margins and a slight reduction in earnings forecasts for 2026-30, the broker, Morgan Stanley, remains optimistic about the company's profit growth potential. They predict an adjusted net profit compound annual growth rate (CAGR) of 36% from 2024 to 2027, which is significantly higher than that of global peers. Additionally, the broker highlights the company's potential for margin expansion and its leadership position in the industry as reasons for the positive outlook.
Morgan Stanley
Overweight
Price Target
$88 -> $86
2026-02-20
downgrade
The analyst rating for WUXI XDC was assigned an "Overweight" due to several positive factors. Despite a decline in operating margins and a slight reduction in earnings forecasts for 2026-30, the broker, Morgan Stanley, remains optimistic about the company's profit growth potential. They predict an adjusted net profit compound annual growth rate (CAGR) of 36% from 2024 to 2027, which is significantly higher than that of global peers. Additionally, the broker highlights the company's potential for margin expansion and its leadership position in the industry as reasons for the positive outlook.
Nomura
Nomura
upgrade
2026-02-12
Reason
The analyst rating for WUXI BIO (02269.HK) was elevated to "Buy" by Nomura due to a positive profit alert projecting significant revenue growth of 16.7% YoY for 2025, which is slightly above market consensus. Additionally, improvements in gross margin and net profit predictions, both exceeding market expectations, contributed to the positive outlook. The anticipated strong performance of its subsidiary, WUXI XDC, was also highlighted as a key factor in driving revenue growth. Consequently, Nomura raised its target price from $37.36 to $50.54.
Nomura
Price Target
2026-02-12
upgrade
The analyst rating for WUXI BIO (02269.HK) was elevated to "Buy" by Nomura due to a positive profit alert projecting significant revenue growth of 16.7% YoY for 2025, which is slightly above market consensus. Additionally, improvements in gross margin and net profit predictions, both exceeding market expectations, contributed to the positive outlook. The anticipated strong performance of its subsidiary, WUXI XDC, was also highlighted as a key factor in driving revenue growth. Consequently, Nomura raised its target price from $37.36 to $50.54.
BOCOMI
upgrade
$HKD91
2026-01-20
Reason
The analyst rating for WUXI XDC (02268.HK) is based on several positive factors highlighted in the article. The key reasons for the "Buy" rating include:
1. Positive Profit Forecast: WUXI XDC has issued a strong profit forecast for 2025, predicting a revenue increase of over 45% year-on-year due to rapid order growth and the commissioning of Wuxi DP3.
2. Significant Gross Profit Growth: The company anticipates a gross profit surge of more than 70%, driven by improvements in capacity utilization, production efficiency, and effective cost control.
3. Revised Net Profit Expectations: BOCOMI has increased its net profit expectations for WUXI XDC for 2026-27 by 2-3%, reflecting confidence in the company's performance.
4. Aggressive Capacity Expansion Plans: The company's plans for capacity expansion and the latest management guidance suggest a strong growth trajectory.
5. Increased Target Price: BOCOMI raised the target price for WUXI XDC to HKD91, indicating a positive outlook for the stock.
6. Top Recommendation: WUXI XDC has been selected as a top recommendation in the CXO industry, further supporting the positive rating.
Overall, the combination of strong revenue and profit forecasts, effective management strategies, and positive market sentiment contribute to the "Buy" rating.
BOCOMI
Price Target
$HKD91
2026-01-20
upgrade
The analyst rating for WUXI XDC (02268.HK) is based on several positive factors highlighted in the article. The key reasons for the "Buy" rating include:
1. Positive Profit Forecast: WUXI XDC has issued a strong profit forecast for 2025, predicting a revenue increase of over 45% year-on-year due to rapid order growth and the commissioning of Wuxi DP3.
2. Significant Gross Profit Growth: The company anticipates a gross profit surge of more than 70%, driven by improvements in capacity utilization, production efficiency, and effective cost control.
3. Revised Net Profit Expectations: BOCOMI has increased its net profit expectations for WUXI XDC for 2026-27 by 2-3%, reflecting confidence in the company's performance.
4. Aggressive Capacity Expansion Plans: The company's plans for capacity expansion and the latest management guidance suggest a strong growth trajectory.
5. Increased Target Price: BOCOMI raised the target price for WUXI XDC to HKD91, indicating a positive outlook for the stock.
6. Top Recommendation: WUXI XDC has been selected as a top recommendation in the CXO industry, further supporting the positive rating.
Overall, the combination of strong revenue and profit forecasts, effective management strategies, and positive market sentiment contribute to the "Buy" rating.
CMBI
CMBI
maintain
$74 -> $88
2026-01-19
Reason
The analyst rating for WUXI XDC (02268.HK) is a "Buy" due to a positive profit alert projecting significant growth in revenue and net profit for 2025. Specifically, the company anticipates at least a 45% increase in revenue and over a 38% rise in net profit year-over-year. Additionally, the adjusted net profit is expected to rise by over 45%, potentially exceeding 65% when excluding foreign exchange effects. CMBI has raised its target price from HKD74 to HKD88, reflecting confidence in the company's growth trajectory, with forecasts indicating continued revenue and profit increases through 2027.
CMBI
Price Target
$74 -> $88
2026-01-19
maintain
The analyst rating for WUXI XDC (02268.HK) is a "Buy" due to a positive profit alert projecting significant growth in revenue and net profit for 2025. Specifically, the company anticipates at least a 45% increase in revenue and over a 38% rise in net profit year-over-year. Additionally, the adjusted net profit is expected to rise by over 45%, potentially exceeding 65% when excluding foreign exchange effects. CMBI has raised its target price from HKD74 to HKD88, reflecting confidence in the company's growth trajectory, with forecasts indicating continued revenue and profit increases through 2027.
Nomura
Nomura
maintain
$82.72
2026-01-16
Reason
The analyst rating from Nomura is a Buy, but the reason for the cautious outlook is that they predict WUXI XDC's 2H25 results may fall short of market expectations. Specifically, they estimate that the company's sales revenue for 2H25 will grow by 33% YoY to RMB3.18 billion, which is below the market expectation of RMB3.33 billion and also lower than their previous estimate of RMB3.48 billion. Despite this, they still maintain a positive long-term outlook, as indicated by the positive profit alert issued by WUXI XDC forecasting significant year-over-year increases in revenue and profits.
Nomura
Price Target
$82.72
2026-01-16
maintain
The analyst rating from Nomura is a Buy, but the reason for the cautious outlook is that they predict WUXI XDC's 2H25 results may fall short of market expectations. Specifically, they estimate that the company's sales revenue for 2H25 will grow by 33% YoY to RMB3.18 billion, which is below the market expectation of RMB3.33 billion and also lower than their previous estimate of RMB3.48 billion. Despite this, they still maintain a positive long-term outlook, as indicated by the positive profit alert issued by WUXI XDC forecasting significant year-over-year increases in revenue and profits.
JPMorgan
JPMorgan
Overweight
maintain
{"WUXI_XDC": "$74", "WUXI_APPTEC": "$142", "WUXI_BIO": "$37"}
2025-12-05
Reason
The analyst rating for the stocks in China's CXO industry, including WUXI APPTEC, WUXI XDC, and WUXI BIO, is based on a few key factors highlighted in JPMorgan's research report. The recent strong rebound in these stocks is attributed to a relief from market concerns regarding potential legislative changes in the US, specifically the US Biosecure Act and the National Defense Authorization Act. Additionally, JPMorgan believes that the easing of geopolitical tensions between the US and China, particularly following a phone call between US President Donald Trump and Chinese President Xi Jinping, will positively impact the development of China's CXO industry. As a result, JPMorgan has rated these stocks as Overweight and set target prices for each.
JPMorgan
Overweight
Price Target
{"WUXI_XDC": "$74", "WUXI_APPTEC": "$142", "WUXI_BIO": "$37"}
2025-12-05
maintain
The analyst rating for the stocks in China's CXO industry, including WUXI APPTEC, WUXI XDC, and WUXI BIO, is based on a few key factors highlighted in JPMorgan's research report. The recent strong rebound in these stocks is attributed to a relief from market concerns regarding potential legislative changes in the US, specifically the US Biosecure Act and the National Defense Authorization Act. Additionally, JPMorgan believes that the easing of geopolitical tensions between the US and China, particularly following a phone call between US President Donald Trump and Chinese President Xi Jinping, will positively impact the development of China's CXO industry. As a result, JPMorgan has rated these stocks as Overweight and set target prices for each.
Goldman Sachs
Goldman Sachs
Neutral
maintain
$63.3
2025-11-05
Reason
The analyst rating for WUXI XDC was set at Neutral by Goldman Sachs due to several factors. While the company is experiencing strong order momentum and solid customer demand, particularly from US clients, there are concerns regarding the potential lower gross margin in the second half of 2025 compared to the first half. Additionally, although the company is actively negotiating contracts for its Singapore facility, the revenue contribution from this facility is expected to be limited before 2027 due to the time required for production capacity expansion. Despite ongoing output and workforce expansions, these factors contributed to the Neutral rating, with a target price set at $63.3.
Goldman Sachs
Neutral
Price Target
$63.3
2025-11-05
maintain
The analyst rating for WUXI XDC was set at Neutral by Goldman Sachs due to several factors. While the company is experiencing strong order momentum and solid customer demand, particularly from US clients, there are concerns regarding the potential lower gross margin in the second half of 2025 compared to the first half. Additionally, although the company is actively negotiating contracts for its Singapore facility, the revenue contribution from this facility is expected to be limited before 2027 due to the time required for production capacity expansion. Despite ongoing output and workforce expansions, these factors contributed to the Neutral rating, with a target price set at $63.3.
Valuation Metrics
Forward PE
5Y Average PE
30.77
Current PE
37.74
Overvalued PE
41.42
Undervalued PE
20.13
Forward EV/EBITDA
5Y Average EV/EBITDA
24.01
Current EV/EBITDA
29.26
Overvalued EV/EBITDA
33.25
Undervalued EV/EBITDA
14.77
Forward PS
5Y Average PS
7.59
Current PS
9.83
Overvalued PS
10.15
Undervalued PS
5.04
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
No data
Short Selling
People Also Watch